Cooper Companies (NASDAQ:COO) Earns Market Perform Rating from William Blair

Posted by Francis Steltz on Sep 10th, 2026

Cooper Companies (NASDAQ:COO – Get Free Report)‘s stock had its “market perform” rating reissued by research analysts at William Blair in a report issued on Thursday, MarketBeat reports.

COO has been the subject of several other research reports. Weiss Ratings restated a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. Stifel Nicolaus set a $70.00 price objective on Cooper Companies in a report on Thursday. Needham & Company LLC cut their price objective on Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a research note on Thursday. UBS Group reduced their target price on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a report on Thursday. Finally, BNP Paribas Exane decreased their target price on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a research report on Monday, June 8th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $74.33.

View Our Latest Stock Analysis on COO

Cooper Companies Price Performance

NASDAQ COO traded down $9.64 on Thursday, hitting $53.84. The company had a trading volume of 2,969,847 shares, compared to its average volume of 2,346,635. The company has a market capitalization of $10.50 billion, a PE ratio of 45.81, a PEG ratio of 1.77 and a beta of 0.82. The company’s fifty day moving average price is $72.42 and its 200-day moving average price is $70.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. Cooper Companies has a 12-month low of $51.01 and a 12-month high of $89.83.

Cooper Companies (NASDAQ:COO – Get Free Report) last posted its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the business posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, analysts predict that Cooper Companies will post 4.63 earnings per share for the current year.

Cooper Companies declared that its board has authorized a stock buyback program on Wednesday, September 9th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Institutional Trading of Cooper Companies

Several large investors have recently bought and sold shares of the business. Root Financial Partners LLC lifted its stake in Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares in the last quarter. Avalon Trust Co purchased a new stake in shares of Cooper Companies in the second quarter valued at approximately $25,000. SJS Investment Consulting Inc. increased its holdings in shares of Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares during the last quarter. Elevation Wealth Partners LLC increased its holdings in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC purchased a new position in Cooper Companies during the second quarter worth approximately $30,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

Positive Sentiment: COO reported fiscal Q3 adjusted EPS of $1.15, above the $1.11-$1.12 analyst consensus. GAAP EPS was $2.24, helped by a $307.2 million benefit from the favorable completion of a U.K. tax examination. Free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
Positive Sentiment: The board expanded the share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares. Management also said it remains open to strategic alternatives that could create shareholder value. CooperCompanies Completes Strategic Review
Neutral Sentiment: Third-quarter revenue rose roughly 1% year over year to $1.066 billion, with CooperVision revenue flat at $717 million and CooperSurgical revenue up 2% to $349.2 million. The results show continued profitability but limited underlying growth.
Negative Sentiment: Revenue missed the approximately $1.10 billion consensus estimate, while fiscal 2026 adjusted EPS guidance was cut to $4.51-$4.55 from expectations near $4.63. Fourth-quarter EPS guidance of $1.05-$1.09 also trails the roughly $1.20 consensus. Analysts Lower Forecasts Following Q3 Results
Negative Sentiment: CooperCompanies ended its strategic review by retaining CooperSurgical because potential offers were not attractive enough. Investors appear disappointed that the company will not receive sale proceeds, amid valuation pressure from a new non-hormonal IUD competitor and recent fertility-litigation costs.
Negative Sentiment: Analysts responded by lowering price targets, including Needham to $73 from $86 and Bank of America to $65 from $80. Bank of America maintained a neutral rating, while the forecast reductions reinforced concerns about near-term growth.

Cooper Companies Company Profile

(Get Free Report)

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.